UBS AM’s Cytek Biosciences CTKB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$6.6K Buy
1,108
+526
+90% +$2.49K ﹤0.01% 3870
2026
Q2
$2.58K Hold
582
– – ﹤0.01% 3503
2026
Q1
$2.54K Sell
582
-250
-30% -$1.18K ﹤0.01% 3558
2025
Q4
$4.2K Buy
+832
New +$3.86K ﹤0.01% 3009
2025
Q3
– Sell
-284,350
Closed -$967K – 2360
2025
Q2
$967K Buy
284,350
+92,726
+48% +$309K ﹤0.01% 2393
2025
Q1
$768K Sell
191,624
-5,434
-3% -$28.2K ﹤0.01% 2404
2024
Q4
$1.28M Buy
197,058
+22,433
+13% +$134K ﹤0.01% 2261
2024
Q3
$967K Sell
174,625
-24,528
-12% -$139K ﹤0.01% 2413
2024
Q2
$1.11M Buy
199,153
+75,022
+60% +$451K ﹤0.01% 2323
2024
Q1
$833K Buy
124,131
+1,015
+0.8% +$8.03K ﹤0.01% 2099
2023
Q4
$1.12M Buy
123,116
+11,593
+10% +$73K ﹤0.01% 1964
2023
Q3
$616K Buy
111,523
+47,428
+74% +$380K ﹤0.01% 2204
2023
Q2
$589K Hold
64,095
– – ﹤0.01% 2254
2023
Q1
$589K Buy
64,095
+1,063
+2% +$11.4K ﹤0.01% 2254
2022
Q4
$644K Sell
63,032
-6,790
-10% -$91.3K ﹤0.01% 2068
2022
Q3
$1.03M Buy
69,822
+5,865
+9% +$76.2K ﹤0.01% 1954
2022
Q2
$686K Buy
+63,957
New +$637K ﹤0.01% 2156

Other funds holding CTKB

UBS AM's CTKB Position: Q3 2026 in Review

UBS AM increased its Cytek Biosciences (CTKB) stake by 90% in Q3 2026, buying an estimated $2.49K and bringing the position to 1,108 shares worth $6.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3870.

UBS AM first reported a position in CTKB in Q2 2022 and has held it in 17 quarters since. The position peaked at $1.28M in Q4 2024. 128 funds tracked by Wall St. Rank hold CTKB as of Q3 2026.

  • UBS AM held 1,108 shares of Cytek Biosciences worth $6.6K as of Q3 2026.
  • UBS AM bought 526 Cytek Biosciences shares in Q3 2026, an estimated $2.49K.
  • Cytek Biosciences made up ﹤0.01% of UBS AM's portfolio in Q3 2026, its #3870 holding.
  • UBS AM first reported a position in Cytek Biosciences in Q2 2022 and has held it in 17 quarters since.
  • UBS AM's Cytek Biosciences position peaked at $1.28M in Q4 2024.
  • 128 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2026.

Based on UBS AM's 13F filing for Q3 2026, filed 16 Nov 2026.